Pyxis Oncology, Inc. Capital Units, Authorized
Pyxis Oncology, Inc. (PYXS) had Capital Units, Authorized of 200.00 million shares as of 2021-10-08, per its 10-K filed 2022-03-29.
Discontinued › Notes › Equity
us-gaap:CapitalUnitsAuthorized · last filed 2022-03-29
- 2021-10-08: Capital Units, Authorized 200.00M shares.
| Period end | Capital Units, Authorized |
|---|---|
| 2021-10-08 | 200.00M shares 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |